Induction of protective immunity by vaccination against Chlamydia trachomatis using the major outer membrane protein adjuvanted with CpG oligodeoxynucleotide coupled to the nontoxic B subunit of cholera toxin

Vaccine

Volumn 27, Issue 44, 2009, Pages 6239-6246

  Cheng, Chunmei ^a   Bettahi, Ilham ^a   Cruz Fisher, Maria I ^a   Pal, Sukumar ^a   Jain, Pooja ^a   Jia, Zhenyu ^a   Holmgren, Jan ^b   Harandi, Ali M ^b   de la Maza, Luis M ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF GOTHENBURG   (Sweden)

Author keywords

Chlamydia trachomatis; CTB CpG adjuvant; Vaccine

Indexed keywords

CHOLERA TOXIN B SUBUNIT; GAMMA INTERFERON; IMMUNOGLOBULIN G; OLIGODEOXYNUCLEOTIDE; OUTER MEMBRANE PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ARTICLE; BODY WEIGHT; CD4+ T LYMPHOCYTE; CELLULAR IMMUNITY; CHLAMYDIA TRACHOMATIS; CHLAMYDIASIS; CONTROLLED STUDY; DRUG EFFICACY; DRUG FORMULATION; FEMALE; LUNG WEIGHT; MOUSE; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE; VACCINATION;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIBODIES, BACTERIAL; BACTERIAL VACCINES; BODY WEIGHT; CELL PROLIFERATION; CHLAMYDIA INFECTIONS; CHLAMYDIA TRACHOMATIS; CHOLERA TOXIN; FEMALE; IMMUNITY, CELLULAR; IMMUNITY, HUMORAL; IMMUNOGLOBULIN G; LUNG; MICE; MICE, INBRED BALB C; OLIGODEOXYRIBONUCLEOTIDES; PORINS; SPLEEN; T-LYMPHOCYTES;

EID: 70349973772     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2009.07.108     Document Type: Article

References (51)

1. World Health Organization. Global prevalence and incidence of selected curable sexually transmitted diseases: overview and estimates. Geneva; 2001.
2. Trends in reportable sexually transmitted diseases in the United States, 2007. National Surveillance Data for Chlamydia, Gonorrhea, and Syphilis. United States: Centers for Disease Control and Prevention; 2007. p. 1-7.
3. Miller W.C., Ford C.A., Morris M., Handcock M.S., Schmitz J.L., Hobbs M.M., et al. Prevalence of chlamydial and gonococcal infections among young adults in the United States. JAMA 291 18 (2004) 2229-2236
4. Nigg C. An unidentified virus which produces pneumonia and systemic infection in mice. Science 95 2454 (1942) 49-50
5. Pal S., Davis H.L., Peterson E.M., and de la Maza L.M. Immunization with the Chlamydia trachomatis mouse pneumonitis major outer membrane protein by use of CpG oligodeoxynucleotides as an adjuvant induces a protective immune response against an intranasal chlamydial challenge. Infect Immun 70 9 (2002) 4812-4817
6. Pal S., Peterson E.M., and de la Maza L.M. Vaccination with the Chlamydia trachomatis major outer membrane protein can elicit an immune response as protective as that resulting from inoculation with live bacteria. Infect Immun 73 12 (2005) 8153-8160
7. Adamsson J., Lindblad M., Lundqvist A., Kelly D., Holmgren J., and Harandi A.M. Novel immunostimulatory agent based on CpG oligodeoxynucleotide linked to the nontoxic B subunit of cholera toxin. J Immunol 176 8 (2006) 4902-4913
8. Fujihashi K., Koga T., van Ginkel F.W., Hagiwara Y., and McGhee J.R. A dilemma for mucosal vaccination: efficacy versus toxicity using enterotoxin-based adjuvants. Vaccine 20 19-20 (2002) 2431-2438
9. Spangler B.D. Structure and function of cholera toxin and the related Escherichia coli heat-labile enterotoxin. Microbiol Rev 56 4 (1992) 622-647
10. Snider D.P. The mucosal adjuvant activities of ADP-ribosylating bacterial enterotoxins. Crit Rev Immunol 15 3-4 (1995) 317-348
11. Marinaro M., Staats H.F., Hiroi T., Jackson R.J., Coste M., Boyaka P.N., et al. Mucosal adjuvant effect of cholera toxin in mice results from induction of T helper 2 (Th2) cells and IL-4. J Immunol 155 10 (1995) 4621-4629
12. Marinaro M., Boyaka P.N., Finkelman F.D., Kiyono H., Jackson R.J., Jirillo E., et al. Oral but not parenteral interleukin (IL)-12 redirects T helper 2 (Th2)-type responses to an oral vaccine without altering mucosal IgA responses. J Exp Med 185 3 (1997) 415-427
13. Wang H., Rayburn E., and Zhang R. Synthetic oligodeoxynucleotides containing deoxycytidyl-deoxyguanosine dinucleotides (CpG ODNs) and modified analogs as novel anticancer therapeutics. Curr Pharmaceut Des 11 22 (2005) 2889-2907
14. Nouri-Aria K.T. Recent progress in allergen immunotherapy. Iran J Immunol 5 1 (2008) 1-24
15. Harandi A.M., and Holmgren J. CpG DNA as a potent inducer of mucosal immunity: implications for immunoprophylaxis and immunotherapy of mucosal infections. Curr Opin Investig Drugs 5 2 (2004) 141-145
16. Nystrom-Asklin J., Adamsson J., and Harandi A.M. The adjuvant effect of CpG oligodeoxynucleotide linked to the non-toxic B subunit of cholera toxin for induction of immunity against H. pylori in mice. Scand J Immunol 67 5 (2008) 431-440
17. Pal S., Fielder T.J., Peterson E.M., and de la Maza L.M. Protection against infertility in a BALB/c mouse salpingitis model by intranasal immunization with the mouse pneumonitis biovar of Chlamydia trachomatis. Infect Immun 62 8 (1994) 3354-3362
18. Peterson E.M., Zhong G.M., Carlson E., and de la Maza L.M. Protective role of magnesium in the neutralization by antibodies of Chlamydia trachomatis infectivity. Infection and immunity 56 4 (1988) 885-891
19. De Pascalis R., Taylor B.C., and Elkins K.L. Diverse myeloid and lymphoid cell subpopulations produce gamma interferon during early innate immune responses to Francisella tularensis live vaccine strain. Infect Immun 76 9 (2008) 4311-4321
20. eBioscience. Intracellular Cytokine Staining Protocol; 2008.
21. Department of Statistics and Mathematics of the Wu Wien. Available from: http://www.r-project.org/.
22. Xu D., Liu H., and Komai-Koma M. Direct and indirect role of toll-like receptors in T cell mediated immunity. Cell Mol Immunol 1 4 (2004) 239-246
23. Karlsen T.H., Sommerfelt H., Klomstad S., Andersen P.K., Strand T.A., Ulvik R.J., et al. Intestinal and systemic immune responses to an oral cholera toxoid B subunit whole-cell vaccine administered during zinc supplementation. Infect Immun 71 7 (2003) 3909-3913
24. Stanford M., Whittall T., Bergmeier L.A., Lindblad M., Lundin S., Shinnick T., et al. Oral tolerization with peptide 336-351 linked to cholera toxin B subunit in preventing relapses of uveitis in Behcet's disease. Clin Exp Immunol 137 1 (2004) 201-208
25. Wassen L., and Jertborn M. Kinetics of local and systemic immune responses after vaginal immunization with recombinant cholera toxin B subunit in humans. Clin. Diag Lab Immunol 12 3 (2005) 447-452
26. Holmgren J., Adamsson J., Anjuere F., Clemens J., Czerkinsky C., Eriksson K., et al. Mucosal adjuvants and anti-infection and anti-immunopathology vaccines based on cholera toxin, cholera toxin B subunit and CpG DNA. Immunol Lett 97 2 (2005) 181-188
27. Sanchez J., and Holmgren J. Cholera toxin structure, gene regulation and pathophysiological and immunological aspects. Cell Mol Life Sci 65 9 (2008) 1347-1360
28. Morrison R.P., Feilzer K., and Tumas D.B. Gene knockout mice establish a primary protective role for major histocompatibility complex class II-restricted responses in Chlamydia trachomatis genital tract infection. Infect Immun 63 12 (1995) 4661-4668
29. Morrison S.G., Su H., Caldwell H.D., and Morrison R.P. Immunity to murine Chlamydia trachomatis genital tract reinfection involves B cells and CD4(+) T cells but not CD8(+) T cells. Infect Immun 68 12 (2000) 6979-6987
30. Perry L.L., Feilzer K., and Caldwell H.D. Immunity to Chlamydia trachomatis is mediated by T helper 1 cells through IFN-gamma-dependent and -independent pathways. J Immunol 158 7 (1997) 3344-3352
31. Wang S., Fan Y., Brunham R.C., and Yang X. IFN-gamma knockout mice show Th2-associated delayed-type hypersensitivity and the inflammatory cells fail to localize and control chlamydial infection. Eur J Immunol 29 11 (1999) 3782-3792
32. Johansson M., Schon K., Ward M., and Lycke N. Genital tract infection with Chlamydia trachomatis fails to induce protective immunity in gamma interferon receptor-deficient mice despite a strong local immunoglobulin A response. Infect Immun 65 3 (1997) 1032-1044
33. Hawkins R.A., Rank R.G., and Kelly K.A. A Chlamydia trachomatis-specific Th2 clone does not provide protection against a genital infection and displays reduced trafficking to the infected genital mucosa. Infect Immun 70 9 (2002) 5132-5139
34. Perry L.L., Feilzer K., Hughes S., and Caldwell H.D. Clearance of Chlamydia trachomatis from the murine genital mucosa does not require perforin-mediated cytolysis or Fas-mediated apoptosis. Infect Immun 67 3 (1999) 1379-1385
35. Kim S.K., Devine L., Angevine M., DeMars R., and Kavathas P.B. Direct detection and magnetic isolation of Chlamydia trachomatis major outer membrane protein-specific CD8+ CTLs with HLA class I tetramers. J Immunol 165 12 (2000) 7285-7292
36. Kim S.K., Angevine M., Demick K., Ortiz L., Rudersdorf R., Watkins D., et al. Induction of HLA class I-restricted CD8+ CTLs specific for the major outer membrane protein of Chlamydia trachomatis in human genital tract infections. J Immunol 162 11 (1999) 6855-6866
37. Roan N.R., and Starnbach M.N. Antigen-specific CD8+ T cells respond to Chlamydia trachomatis in the genital mucosa. J Immunol 177 11 (2006) 7974-7979
38. Holland M.J., Conway D.J., Blanchard T.J., Mahdi O.M., Bailey R.L., Whittle H.C., et al. Synthetic peptides based on Chlamydia trachomatis antigens identify cytotoxic T lymphocyte responses in subjects from a trachoma-endemic population. Clin Exp Immunol 107 1 (1997) 44-49
39. Starnbach M.N., Bevan M.J., and Lampe M.F. Murine cytotoxic T lymphocytes induced following Chlamydia trachomatis intraperitoneal or genital tract infection respond to cells infected with multiple serovars. Infect Immun 63 9 (1995) 3527-3530
40. Starnbach M.N., Bevan M.J., and Lampe M.F. Protective cytotoxic T lymphocytes are induced during murine infection with Chlamydia trachomatis. J Immunol 153 11 (1994) 5183-5189
41. Igietseme J.U., Black C.M., and Caldwell H.D. Chlamydia vaccines: strategies and status. BioDrugs 16 1 (2002) 19-35
42. Morrison R.P., and Caldwell H.D. Immunity to murine chlamydial genital infection. Infect Immun 70 6 (2002) 2741-2751
43. Coutelier J.P., van der Logt J.T., Heessen F.W., Warnier G., and Van Snick J. IgG2a restriction of murine antibodies elicited by viral infections. J Exp Med 165 1 (1987) 64-69
44. Mosmann TRaC R.L. Th1 and Th2 cells: different patterns of lymphokine secretion lead to different functional properties. Ann Rev Immunol 7 (1989) 145-173
45. Pal S., Peterson E.M., and de la Maza L.M. Vaccination of newborn mice induces a strong protective immune response against respiratory and genital challenges with Chlamydia trachomatis. Vaccine 23 46-47 (2005) 5351-5358
46. Punnonen R., Terho P., Nikkanen V., and Meurman O. Chlamydial serology in infertile women by immunofluorescence. Fertil Steril 31 6 (1979) 656-659
47. Su H., Feilzer K., Caldwell H.D., and Morrison R.P. Chlamydia trachomatis genital tract infection of antibody-deficient gene knockout mice. Infect Immun 65 6 (1997) 1993-1999
48. Morrison S.G., and Morrison R.P. The protective effect of antibody in immunity to murine chlamydial genital tract reinfection is independent of immunoglobulin A. Infect Immun 73 9 (2005) 6183-6186
49. Pal S., Bravo J., Peterson E.M., and de la Maza L.M. Protection of wild-type and severe combined immunodeficiency mice against an intranasal challenge by passive immunization with monoclonal antibodies to the Chlamydia trachomatis mouse pneumonitis major outer membrane protein. Infect Immun 76 12 (2008) 5581-5587
50. Pal S., Theodor I., Peterson E.M., and de la Maza L.M. Monoclonal immunoglobulin A antibody to the major outer membrane protein of the Chlamydia trachomatis mouse pneumonitis biovar protects mice against a chlamydial genital challenge. Vaccine 15 5 (1997) 575-582
51. Brunham R.C., Kuo C.C., Cles L., and Holmes K.K. Correlation of host immune response with quantitative recovery of Chlamydia trachomatis from the human endocervix. Infect Immun 39 3 (1983) 1491-1494